Available to mentor
Dr. Ljungman has a long-standing interest in carcinogenesis, radiation biology, DNA damage responses and regulation of transcription. A major goal of the lab is to elucidate basic mechanisms that ultimately could help better understand human diseases and in the development of improved therapeutics. The Ljungman lab has developed the Bru-seq technology platform to assess nascent RNA synthesis and stability in cells as well as splicing kinetics, transcription elongation rates and the mapping of transcription start sites and enhancers. These techniques provide novel information about the transcription process that cannot be obtained with traditional steady-state RNA-based approaches. The Ljungman lab is participating in ENCODE 4 as a Mapping Center.
-
Postdoctoral fellowStanford University, United States, 1994
-
Center MemberCenter for Computational Medicine and Bioinformatics
-
Center MemberRogel Cancer Center
-
Center MemberPrecision Health Initiative
With the Bru-seq technology platform, the Ljungman lab are exploring many basic biological pathways involved in DNA damage and repair, acute cellular responses, epigenetics, differentiation, aging, cancer, neurodegenerative diseases such as ALS and autism. They are also collaborating with medicinal chemists to interrogate mechanisms of action of novel therapeutic drugs and are developing specific inhibitors of the RNA exosome as cancer therapeutic drugs. With the Bru-seq techniques, the Ljungman lab collaborates with many labs at the university and from over 10 different countries.
-
Barravecchia I, Sharma M, Teis R, Cruz J, Mumby R, Ziemke E, Espinoza C, Magnuson B, Ljungman M, Koschmann C, Whitehead C, Sebolt-Leopold J, Galban S. Molecular Cancer Therapeutics, 2023 Dec 1; 22 (12_Supplement): c150 - c150.Journal ArticleAbstract C150: Targeted inhibition of homologous recombination and nonhomologous end joining in diffuse intrinsic pontine gliomas to prevent tumor recurrence
DOI:10.1158/1535-7163.targ-23-c150 -
Wang Z, Coban B, Wu H, Chouaref J, Daxinger L, Paulsen MT, Ljungman M, Smid M, Martens JWM, Danen EHJ. Cell Commun Signal, 2023 Jan 23; 21 (1): 15Journal ArticleGRHL2-controlled gene expression networks in luminal breast cancer.
DOI:10.1186/s12964-022-01029-5 PMID: 36691073 -
Barravecchia I, Sharma M, Teis R, Cruz J, Mumby R, Ziemke E, Espinoza C, Krishnamoorthy V, Magnuson B, Ljungman M, Koschmann C, Whitehead C, Sebolt-Leopold J, Galban S. Neuro-Oncology, 2023 Nov 10; 25 (Supplement_5): v105 - v106.Journal ArticleDDDR-05. TARGETED INHIBITION OF DNA REPAIR AND SURVIVAL SIGNALING IN DIFFUSE INTRINSIC PONTINE GLIOMAS
DOI:10.1093/neuonc/noad179.0399 -
Sharma M, Barravecchia I, Teis R, Cruz J, Mumby R, Ziemke EK, Espinoza C, Krishnamoorthy V, Magnuson B, Ljungman M, Koschmann C, Whitehead C, Sebolt-Leopold J, Galban S. Molecular Cancer Therapeutics, 2023 Nov 1;Journal ArticleTargeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to prevent Tumor Recurrence
-
Sharma M, Barravecchia I, Magnuson B, Ferris SF, Apfelbaum A, Mbah NE, Cruz J, Krishnamoorthy V, Teis R, Kauss M, Koschmann C, Lyssiotis CA, Ljungman M, Galban S. Neoplasia, 2023 Oct;Journal ArticleHistone H3 K27M-mediated Regulation of Cancer Cell Stemness and Differentiation in Diffuse Midline Glioma
-
Sharma M, Barravecchia I, Magnuson B, Ferris SF, Apfelbaum A, Mbah NE, Cruz J, Krishnamoorthy V, Teis R, Kauss M, Koschmann C, Lyssiotis CA, Ljungman M, Galban S. Neoplasia, 2023 Oct; 44: 100931Journal ArticleHistone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma.
DOI:10.1016/j.neo.2023.100931 PMID: 37647805 -
Xu Y, Xue D, Kyani A, Bankhead A, Roy J, Ljungman M, Neamati N. ACS Pharmacol Transl Sci, 2023 Aug 11; 6 (8): 1164 - 1181.Journal ArticleFirst-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment of Pancreatic Cancer.
DOI:10.1021/acsptsci.3c00069 PMID: 37588763 -
Lu S, Kim HS, Cao Y, Bedi K, Zhao L, Narayanan IV, Magnuson B, Gu Y, Yang J, Yi Z, Babaniamansour S, Shameon S, Xu C, Paulsen MT, Qiu P, Jeyarajan S, Ljungman M, Thomas D, Dou Y, Crawford H, di Magliano MP, Ge K, Yang B, Shi J. Int J Cancer, 2023 Aug 1; 153 (3): 552 - 570.Journal ArticleKMT2D links TGF-β signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity.
DOI:10.1002/ijc.34528 PMID: 37140208